The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) kicked off 2026 with a one‑day symposium, “The Preclinical Pipeline: Radiochemistry from Concept to Clinic.” Held at the Australian Institute for Bioengineering and Nanotechnology, the event brought together researchers, industry partners, and collaborators committed to advancing targeted radiopharmaceuticals.

A keynote address from Professor Jason Lewis (MSKCC) set the tone for the day, followed by research presentations spanning chelator design, radiochemistry innovations, and radiobiology. Dr Ellen van Dam (Clarity Pharmaceuticals) and Ben Hughes (Therapeutic Innovation Australia) joined Jason for a lively expert panel discussion moderated by AMTAR postdoc Dr James Wood, exploring challenges and opportunities in translating radiochemical concepts into clinical impact.

The symposium provided an invaluable opportunity to welcome many of AMTAR’s industry partners and collaborators in person, while colleagues from across Australia joined online. The strong engagement across sectors and locations reflects the growing momentum of Australia’s radiopharmaceutical ecosystem.

Following the formal program, project teams met to refine goals and align strategies—laying the groundwork for a productive and impactful 2026 for the Hub.